Gilead has secured another synthetic lethal therapy, handing $80 million upfront for the global rights to a clinic-ready cancer drug from China’s Genhouse Bio.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Gilead has secured another synthetic lethal therapy, handing $80 million upfront for the global rights to a clinic-ready cancer drug from China’s Genhouse Bio.